Introduction: Little research to date has examined antihyperglycemic agent (AHA) utilization among patients with type 2 diabetes mellitus (T2DM) around transitions of care from inpatient to outpatient settings. Discontinuity of care between inpatient and outpatient settings has been associated with adverse clinical outcomes, so a better understanding of AHA treatment patterns is important. Methods: This retrospective study assessed AHA utilization among a sample of United States adults with a T2DM diagnosis listed on an inpatient admission during 2010-2012 in the MarketScan Ò Hospital Drug database (Truven Health Analytics). AHA use while hospitalized was measured from inpatient medication administration records in that database. AHA use pre-and post-hospitalization was assessed from outpatient retail and mail order pharmacy claims in the MarketScan Commercial and Medicare Supplemental databases, which contain de-identified insurance claims from large employers and health plans. The hospital and claims databases are linked, allowing patients to be followed across transitions of care. Results: The study sample (N = 8144) was 53% male, with a mean age of 66 years. Twenty-one percent had no T2DM diagnosis or claims for AHAs in the 90-day pre-hospitalization period suggesting they may have been newly diagnosed at the time of admission. Most (83%) patients used AHAs while hospitalized, but the proportions with AHA claims 30 days pre-and post-hospitalization were only 53% and 40%, respectively. Biguanides and sulfonylureas were the most common outpatient agents. Most (70%) patients who had no AHA utilization pre-hospitalization continued to have no AHA utilization post-hospitalization. About half the patients with AHA claims pre-hospitalization did not have any AHA claims post-discharge. Electronic supplementary material The online version of this article (
INTRODUCTION
In the United States (US), the goal of optimizing treatment strategies for type 2 diabetes mellitus (T2DM) has grown in urgency with the epidemic rise of the disease. In 2012, an estimated 9.3% of the US population had diabetes, compared to 8.3% in 2010 [1] . The number of hospitalizations each year among people with diabetes also has risen substantially, from 2.8 million in 1988 to nearly 5.5 million in 2009 [2] . Previous research has suggested that discontinuity of care from the inpatient to the outpatient setting is common, with perhaps as many of 42% of patients discharged on medication not reporting that medication regimen to subsequent outpatient providers [3] . Current treatment guidelines recommend the use of insulin as the preferred treatment for hyperglycemia in the hospital setting, and as a result, hospitalized patients with T2DM often have the other antihyperglycemic agents (AHAs) held and insulin initiated [4] .
However, it remains unclear how hospitalized patients transitioning to outpatient care are being treated following discharge. Whether patients receiving oral AHAs/glucagon-like peptide-1 receptor agonists (GLP-1s) prior to hospitalization resume their use, and whether patients who were undiagnosed or untreated before their hospitalization begin antihyperglycemic therapy after discharge, have been poorly studied. With the tremendous increase in diabetes and focus on linking continuity of care with adverse clinical outcomes, it is imperative to better understand which therapeutic strategies may lead to the best outcomes for patients with T2DM.
Determining current treatment patterns around transitions of care represents the first step toward optimizing therapy across treatment settings.
To assess AHA utilization patterns around inpatient to outpatient transitions of care, we conducted a retrospective database study among a sample of US adults hospitalized with a diagnosis of T2DM during 2010-2012.
METHODS
This study was a retrospective analysis of de-identified medical and pharmacy data from the 2010-2012 MarketScan Ò Hospital Drug, as the basis of this study that followed patients across outpatient and inpatient settings of care.
Patients selected for the study were required to meet the following criteria: All variables were tabulated for descriptive review. Frequencies and percentages were calculated for categorical variables and means and standard deviations were examined for continuous variables. Descriptive analysis was undertaken to compare medication use before, during and after hospitalization.
The study described in this paper was an analysis of de-identified data and did not entail primary research with human or animal subjects. As such, institutional review board approval was not required prior to undertaking this research.
RESULTS

Study Sample Selection and Characteristics
A total of 9580 patients with T2DM were identified in the data source, and 85% (N = 8144) met all inclusion criteria for the study. Study-eligible patients had a mean age of 66 years and 53% were male. Twenty-one percent had no T2DM diagnosis or claims for AHAs in the prior 90 days (Table 1 ). See Table 1 for complete demographics and clinical characteristics.
Index Admission Characteristics
The hospitals in which the index admission occurred tended to be medium (200-499 beds, 57%) or large-sized (500? beds, 30%). Most were non-teaching hospitals (97%) located in urban areas (85%).
A primary or secondary diagnosis of T2DM was required on the index hospitalization for study inclusion, but the primary reason for admission was not diabetes related for most patients in the study sample ( 
AHA Utilization
Almost half (47%) of patients with T2DM did not have any AHA claims in the 30 days prior to hospitalization, and this proportion rose to about 60% in the 30 days following discharge (Table 3) . Seventeen percent of patients had no AHA utilization while in the hospital.
Biguanides (i.e., metformin) were the most commonly filled oral AHAs pre-and post-hospitalization, followed by the sulfonylureas and dipeptidyl peptidase-4 (DPP-4) inhibitors ( Fig. 1 ). Although only about 15% of patients utilized insulin pre-or post-hospitalization, insulin was utilized by the majority of patients (71%) during hospitalization.
Patients who did not have a claim for AHAs before their hospitalization were unlikely to have one afterward, and patients who had a claim for AHAs before hospitalization often discontinued them following discharge. Of the patients without AHA claims in the 30 days before their hospitalization, 70% continued to have no AHA claims in the 30 days after leaving the hospital (Fig. 2) . Approximately, half of the patients who did have an AHA claim before admission did not have any AHA claims in the 30 days post-discharge. The majority (55%) of patients who were administered AHAs during hospitalization had no AHA claims after leaving the hospital (Fig. 3) . A subgroup analysis that assessed AHA claims among patients with no T2DM diagnosis or claims for AHAs in the 90 days pre-admission (N = 1708) revealed that 77% of AHA antihyperglycemic agent, DPP-4 dipeptidyl peptidase-4. GLP-1 glucagon-like peptide-1 receptor agonist a Patients may use more than one AHA during an observation period; therefore the sum of the percentages may be greater than 100% b 'Other' consists of the following AHA classes; alpha-glucosidase inhibitors, amylin analogs, bile acid sequestrants, dopamine receptor agonists, GLP-1 agonists, and meglitinides; all of which had little utilization (\2%) during the three observation periods these patients had no AHA claims in the 30 days after discharge. The corresponding rate among patients with evidence of either T2DM diagnoses or AHA claims pre-admission (N = 6436) was 55%. In another subgroup analysis among patients whose index In the 60-and 90-day pre-and post-hospitalization analysis, the proportion of patients with no AHA utilization decreased as the follow-up period increased ( discharge. This is concerning because lack of continuity of care has been associated with adverse clinical outcomes, especially in patients with a chronic condition [3] . In a study of Medicare beneficiaries with diabetes hospitalized for acute myocardial infarction, for example, patients discharged without AHA therapy had higher mortality rates 30 days, 6 months, and 1 year post-hospitalization than patients discharged on AHA therapy, even after multivariable adjustment of differences between groups [7] .
It deserves mention that although all patients in the study had a primary or secondary diagnosis of T2DM during the index hospitalization, 21% percent of patients in this study had no healthcare claims with a T2DM diagnosis and no pharmacy claims for AHAs in 90 days prior to their index hospitalization.
Specific clinical details on these patients were not available in the database used for the analysis, but these patients may represent previously undiagnosed patients whose T2DM was initially identified during the index admission. It also is possible they were diagnosed patients treated with lifestyle interventions alone (e.g., diet and exercise but no AHA) who did not incur any healthcare services carrying a T2DM diagnosis in the 90 days prior to hospitalization. These patients had the lowest rates of post-discharge AHA claims but subgroup analyses excluding them entirely did not drastically alter study results; 60% of all patients had no AHA claims in the 30 days post-discharge whereas after this exclusion, 55% of the remaining patients had no AHA claims in the 30 days post-discharge.
Our study finding that 60% of all patients with T2DM had no AHA claims in the 30 days post-discharge (corresponding figures for 60 and 90 days post-discharge were 44, and 35%, respectively) while high, was in line with the small body of previous research examining post-discharge AHA treatment patterns. Wu et al. [8] studied 2160 patients with T2DM who used insulin both in the 30 days before and during hospitalization, identified through retrospective medical records review at a US health system, and found 61% discontinued insulin upon discharge. About 60% of these AHA antihyperglycemic agent, GLP-1 glucagon-like peptide-1 receptor agonist patients were also treated with oral AHAs in the 6 months before hospitalization, but only about 20-25% were treated with oral AHAs in the 60 days post-discharge. Bergenstal et al. [9] assessed pre-and post-admission treatment patterns in a retrospective database analysis of 400 patients, and found 24% had a reduction in AHA regimen after hospitalization. Lipska et al. [7] found that 13.4% of 8791 Medicare patients on AHA therapy at the time of admission for acute myocardial infarction were discharged without such therapy, according to medical record review conducted as part of the National Heart Care Project. In a retrospective chart review of 217 diabetic patients admitted with acute myocardial infarction, Lovig et al.
[10] found 11.5% of these patients were discharged without any AHAs, despite most having no clinical reason to discontinue AHAs.
Griffith et al. [11] [10] conducted medical chart review to assess reasons for AHA discontinuation among diabetic patients hospitalized for myocardial infarction and were unable to find a clear reason for discontinuation for 88% of patients.
That, along with the high proportion of patients with no post-hospitalization AHA in the current and previous studies, suggests hospitalization may not result in an appropriate re-evaluation of therapy. This may be problematic, as patients with T2DM who are hospitalized tend to have poorer glycemic control than comparable patients who are not hospitalized, and the hospitalization may present an opportunity to intervene [12] .
Other literature has suggested that a hospital admission may allow an opportunity to improve long-term diabetes care [13] .
We measured AHA pre-and post-hospitalization utilization based on outpatient pharmacy claims, leaving open the possibility that patients may have received AHAs that do not appear in the data. For example, it is possible that some patients received samples, paid cash for low-cost generic AHA prescriptions such that no claim was generated to their health plan, or had a pre-admission supply of medication that they utilized post-discharge, all of which could make it appear as if patients had no AHA utilization when, in fact, they did use AHAs post-discharge. In addition, inpatient medication utilization for readmitted patients (12% within 30 days; 21% within 90 days) was not captured in our post-discharge medication utilization measures. Treatment non-adherence, for example, patients receiving but not filling AHA prescriptions, also could be reason for the lack of AHA claims since non-adherence is a known issue in this population [14] .
The results of this study are based on patients whose data were captured in the linked MarketScan Hospital Drug database, which may not be generalizable to all individuals with T2DM in the US. The hospitals that contribute to the database are primarily community hospitals and are disproportionately located in the southern region of the US. Most hospitals in which an index admission occurred were non-teaching hospitals (97%) and located in urban areas (85%). AHA utilization patterns at teaching hospitals or rural facilities could be different than seen in our sample.
CONCLUSIONS
The results of this study suggest that a large proportion of hospitalized patients with T2DM may not receive optimal transitions of care in and out of the hospital. Most patients (83%) utilized an AHA while hospitalized but one-half of all patients did not fill an AHA prescription either in the 30 days before or 30 days after hospitalization, and almost one-third of patients did not fill an AHA prescription in the 90 days before or after hospitalization. One-fifth of patients for whom T2DM is listed on a claim associated with their inpatient care had no evidence of being treated for diabetes before their admission, suggesting they may have been 
